Posts tagged Office of Information and Regulatory Affairs.
Blogs
less than a minute
As of Monday March 4, 2024—just three months after the end of its comment period on December 4, 2023—FDA’s rule on regulation of laboratory developed tests (“LDTs”) as medical devices is under review by the Office of Information and Regulatory Affairs (“OIRA”) within the Office of Management and Budget (“OMB”). While review by OIRA is capped at 90 days by Executive Order 12866, there is no minimum period required, and therefore action can be taken any time between now and June.
During this election year, FDA’s efforts to push the rule forward fairly quickly is ...
Blog Editors
Recent Updates
- A Step Closer to the Proposed End of the Self-Affirmed GRAS Pathway
- Imports and the DOJ’s Trade Fraud Task Force: Considerations for the Health Care and Life Sciences Industries
- Federal Appellate Court Upholds Mississippi 340B Contract Pharmacy Protections
- DOJ False Claims Act Priorities: Cybersecurity Is Still on the Radar
- DOJ Launches Cross-Agency Trade Fraud Task Force: What Importers and Businesses Need to Know